Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05579366 · ClinicalTrials.gov registry record · Phase 1
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A Phase 1 study of Non-Small Cell Lung Cancer and Endometrial Cancer, sponsored by Genmab.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 764
- Enrollment target
- 20
- Study locations
NCT05579366: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Endometrial Cancer, sponsored by Genmab.
NCT05579366 is a Phase 1 study of Non-Small Cell Lung Cancer and Endometrial Cancer that is actively recruiting participants, run by Genmab. The registered enrollment target is 764 participants, above the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (17% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05579366, a Phase 1 study of Non-Small Cell Lung Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Genmab.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 764 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Rina-S
Study Locations (20)
California
- University of California Los Angeles Medical Center - Los Angeles
- University of California, San Diego; Moores Cancer Center - San Diego
- USOR Sansum Clinic - Santa Barbara
- Providence Medical Foundation - Santa Rosa
Florida
- USOR Florida Cancer Specialists South - Fort Myers
- USOR Florida Cancer Specialists North - St. Petersburg
- USOR Florida Cancer Specialists East - West Palm Beach
Arizona
- USOR HonorHealth - Phoenix
- USOR Arizona Oncology Associates - Tucson
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institute - Detroit
- START Midwest - Grand Rapids
Georgia
- Augusta University Georgia Cancer Center - Augusta
Kansas
- University of Kansas Medical Center (KUMC) - Westwood
Maryland
- USOR Maryland Oncology Hematology - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 764 participants |
| Start Date | 2022-12-07 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
What NCT05579366 shows while recruiting
NCT05579366 is an interventional study that assigns participants to a tested intervention. The registered 764 participants enrollment target is mid-sized for trials with a published cap, above the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (17% higher).
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05579366 names 20 study sites across 12 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05579366 about?
NCT05579366 is a clinical study titled "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)". This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
What is the current status of trial NCT05579366?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 764 participants. The study started on 2022-12-07. Estimated completion is 2027-10.
What conditions does trial NCT05579366 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Endometrial Cancer, Triple Negative Breast Cancer, Fallopian Tube Cancer, Mesothelioma.
What interventions are being tested in trial NCT05579366?
The interventions under investigation include: Pembrolizumab (DRUG), Bevacizumab (DRUG), Carboplatin (DRUG), Rina-S (DRUG).
Who is sponsoring clinical trial NCT05579366?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05579366 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05579366's enrollment target sits among peer trials
764 38th of 454 higher than 417 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578665 · 764 participants · NA
Human-like Robotic Controllers for Enhanced Motor Learning
- NCT03789552 · 765 participants · Phase 3
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
- NCT07195591 · 766 participants · Phase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- NCT06419374 · 762 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI